Krystal Biotech, Inc. Common Stock (KRYS)
Krystal Biotech, Inc. is a biotechnology company focused on developing gene therapies for dermatological and rare diseases. Established with the goal of advancing genetic medicine, it utilizes a proprietary viral vector platform to deliver gene therapies with the potential to treat conditions that have limited treatment options. The company's approach aims to provide targeted, durable treatments for patients suffering from various skin disorders and other genetic conditions.
Company News
The FDA approved a label update for VYJUVEK, expanding treatment eligibility for dystrophic epidermolysis bullosa (DEB) patients from birth and allowing patients and caregivers to apply the treatment at home with more flexible wound dressing management.
Quoin Pharmaceuticals reported a net loss of $6.28 per share in Q2 2025, which exceeded analyst estimates. The company is developing QRX003, a topical lotion for Netherton Syndrome, and made significant clinical and regulatory progress while increasing R&D spending.
Exelixis' stock has gained 20.7% in the past three months, outperforming the industry and the broader market. The company's lead drug Cabometyx has maintained strong performance, and its pipeline progress is encouraging. Exelixis is also focused on expanding Cabometyx's label and diversifying its portfolio.
Geron's (GERN) shares rise on approval of its first drug. The FDA approves imetelstat for the treatment of adult patients with lower-risk MDS with transfusion-dependent anemia.